Moomoo AIのまとめ
On August 20, 2024, SeaStar Medical Holding Corporation entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, to sell shares of its common stock through an 'at the market' offering program. The sales will be made on the Nasdaq Capital Market or other trading markets for the company's stock. SeaStar Medical will pay a 3.0% commission on gross sales to Wainwright and provide indemnification and expense reimbursement. The agreement includes customary representations, warranties, and conditions, and the company has the discretion to suspend offers or not sell any shares. The offering will continue until either party terminates the agreement. The shares will be issued under the company's shelf registration statement and related prospectus supplements. A prospectus supplement covering the sale of shares worth $25 million was filed with the SEC on the same date. The ATM Agreement is detailed in Exhibit 10.1 of the current report filed with the SEC, and legal opinions from Dorsey & Whitney LLP regarding the share issuance are included as Exhibit 5.1.
On August 20, 2024, SeaStar Medical Holding Corporation entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, to sell shares of its common stock through an 'at the market' offering program. The sales will be made on the Nasdaq Capital Market or other trading markets for the company's stock. SeaStar Medical will pay a 3.0% commission on gross sales to Wainwright and provide indemnification and expense reimbursement. The agreement includes customary representations, warranties, and conditions, and the company has the discretion to suspend offers or not sell any shares. The offering will continue until either party terminates the agreement. The shares will be issued under the company's shelf registration statement and related prospectus supplements. A prospectus supplement covering the sale of shares worth $25 million was filed with the SEC on the same date. The ATM Agreement is detailed in Exhibit 10.1 of the current report filed with the SEC, and legal opinions from Dorsey & Whitney LLP regarding the share issuance are included as Exhibit 5.1.
2024年8月20日、SeaStar Medical Holding CorporationはH.C.ウェインライト＆Co.、LLCと契約を締結し、自社の普通株式を「アット・ザ・マーケット」の提供プログラムを通じて売却する目論見書に入った。売りはナスダック・キャピタル市場やその他の同社株式の取引市場で行われる予定だ。SeaStar Medicalは売り手に対し総売上高の3.0%の手数料を支払い、補償金と経費の精算を提供する。契約には慣例的な表明、保証、および条件が含まれており、会社は買い手を中断する権限やシェアを売却しない権限がある。提供はいずれかの当事者が契約を終了するまで続く予定だ。シェア...すべて展開
2024年8月20日、SeaStar Medical Holding CorporationはH.C.ウェインライト＆Co.、LLCと契約を締結し、自社の普通株式を「アット・ザ・マーケット」の提供プログラムを通じて売却する目論見書に入った。売りはナスダック・キャピタル市場やその他の同社株式の取引市場で行われる予定だ。SeaStar Medicalは売り手に対し総売上高の3.0%の手数料を支払い、補償金と経費の精算を提供する。契約には慣例的な表明、保証、および条件が含まれており、会社は買い手を中断する権限やシェアを売却しない権限がある。提供はいずれかの当事者が契約を終了するまで続く予定だ。シェアは会社の発行登録制度と関連の目論見書の補足書に基づいて発行される。2500万ドル相当のシェア販売をカバーする目論見書の補足書が同日にSECに提出された。ATm契約の詳細は、SECに提出された現行報告書のExhibit 10.1に記載されており、シェアの発行に関するDorsey＆Whitney LLPからの法的意見がExhibit 5.1として含まれている。
役に立った
役に立たない